These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36204777)

  • 1. Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer.
    Mudd GE; Scott H; Chen L; van Rietschoten K; Ivanova-Berndt G; Dzionek K; Brown A; Watcham S; White L; Park PU; Jeffrey P; Rigby M; Beswick P
    J Med Chem; 2022 Nov; 65(21):14337-14347. PubMed ID: 36204777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
    Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K
    Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
    Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L
    J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
    Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
    Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence.
    Khosravanian MJ; Mirzaei Y; Mer AH; Keyhani-Khankahdani M; Abdinia FS; Misamogooe F; Amirkhani Z; Bagheri N; Meyfour A; Jahandideh S; Barpour N; Nikmanesh Y; Shahsavarani H; Abdollahpour-Alitappeh M
    Life Sci; 2024 Sep; 352():122910. PubMed ID: 39002610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
    Wong JL; Rosenberg JE
    Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology.
    Upadhyaya P; Kristensson J; Lahdenranta J; Repash E; Ma J; Kublin J; Mudd GE; Luus L; Jeffrey P; Hurov K; McDonnell K; Keen N
    J Med Chem; 2022 Jul; 65(14):9858-9872. PubMed ID: 35819182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads.
    Mudd GE; Brown A; Chen L; van Rietschoten K; Watcham S; Teufel DP; Pavan S; Lani R; Huxley P; Bennett GS
    J Med Chem; 2020 Apr; 63(8):4107-4116. PubMed ID: 32202781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy.
    Chatterjee S; Sinha S; Kundu CN
    Eur J Pharmacol; 2021 Nov; 911():174516. PubMed ID: 34547246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review.
    Bouleftour W; Guillot A; Magne N
    Mol Cancer Ther; 2022 Apr; 21(4):493-501. PubMed ID: 35131876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioanalysis of the Bicycle
    Tweed JA; Adams-Dam F; Allanson J; Holmes K; Senior R; Xu H; Li M; Bennett G; Jeffrey P
    Bioanalysis; 2024 Feb; 16(3):155-169. PubMed ID: 38088822
    [No Abstract]   [Full Text] [Related]  

  • 13. Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate.
    Mohamed Amar IA; Huvelle S; Douez E; Letast S; Henrion S; Viaud-Massuard MC; Aubrey N; Allard-Vannier E; Joubert N; Denevault-Sabourin C
    Eur J Med Chem; 2022 Feb; 229():114063. PubMed ID: 34974337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BT7480, a novel fully synthetic
    Hurov K; Lahdenranta J; Upadhyaya P; Haines E; Cohen H; Repash E; Kanakia D; Ma J; Kristensson J; You F; Campbell C; Witty D; Kelly M; Blakemore S; Jeffrey P; McDonnell K; Brandish P; Keen N
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
    Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
    Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMAE Delivery Using the
    Bennett G; Brown A; Mudd G; Huxley P; Van Rietschoten K; Pavan S; Chen L; Watcham S; Lahdenranta J; Keen N
    Mol Cancer Ther; 2020 Jul; 19(7):1385-1394. PubMed ID: 32398269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.
    Dosio F; Brusa P; Cattel L
    Toxins (Basel); 2011 Jul; 3(7):848-83. PubMed ID: 22069744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
    Bouleftour W; Sargos P; Magne N
    Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
    Akaiwa M; Dugal-Tessier J; Mendelsohn BA
    Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.